James Larkin

132.2k total citations · 20 hit papers
662 papers, 34.1k citations indexed

About

James Larkin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James Larkin has authored 662 papers receiving a total of 34.1k indexed citations (citations by other indexed papers that have themselves been cited), including 335 papers in Oncology, 302 papers in Molecular Biology and 177 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James Larkin's work include Cancer Immunotherapy and Biomarkers (206 papers), Melanoma and MAPK Pathways (177 papers) and Renal cell carcinoma treatment (148 papers). James Larkin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (206 papers), Melanoma and MAPK Pathways (177 papers) and Renal cell carcinoma treatment (148 papers). James Larkin collaborates with scholars based in United Kingdom, United States and France. James Larkin's co-authors include Caroline Robert, Georgina V. Long, Martin Gore, Matteo S. Carlino, Lavinia Spain, John B.A.G. Haanen, Herbert A. Simon, John McDermott, Solange Peters and Charles Swanton and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

James Larkin

619 papers receiving 33.2k citations

Hit Papers

Renal cell carc... 1980 2026 1995 2010 2017 2017 2014 1980 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Renal cell carcinoma
    2017 1.8k citations Laurence Albigès, James Larkin et al. profile →
  2. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 1.7k citations John B.A.G. Haanen, Caroline Robert et al. profile →
  3. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
    2014 1.5k citations James Larkin, Paolo A. Ascierto et al. profile →
  4. Expert and Novice Performance in Solving Physics Problems
    1980 1.4k citations James Larkin et al. profile →
  5. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
    2012 1.1k citations Caroline Robert, Peter Hersey et al. profile →
  6. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. profile →
  7. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
  8. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
    2017 874 citations Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  9. Immune checkpoint inhibitors in melanoma
    2021 794 citations James Larkin, Georgina V. Long et al. profile →
  10. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
  11. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →
  12. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    2015 688 citations James Larkin et al. profile →
  13. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
    2017 662 citations Samra Turajlic, Martin Gore et al. profile →
  14. Management of toxicities of immune checkpoint inhibitors
    2016 660 citations James Larkin et al. profile →
  15. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 565 citations John B.A.G. Haanen, Caroline Robert et al. profile →
  16. Design and development of NIRSPEC: a near-infrared echelle spectrograph for the Keck II telescope
    1998 442 citations James Larkin et al. profile →
  17. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
    2015 420 citations Eishu Hirata, María Romina Girotti et al. profile →
  18. The First Measurement of Spectral Lines in a Short-Period Star Bound to the Galaxy’s Central Black Hole: A Paradox of Youth
    2003 413 citations James Larkin et al. profile →
  19. Immune checkpoint inhibitors and cardiovascular toxicity
    2018 390 citations Nadia Yousaf, James Larkin et al. profile →
  20. DETECTION AND CHARACTERIZATION OF EXOPLANETS AND DISKS USING PROJECTIONS ON KARHUNEN-LOÈVE EIGENIMAGES
    2012 327 citations James Larkin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Larkin United Kingdom 77 19.2k 12.9k 7.8k 6.0k 3.9k 662 34.1k
Peter Ellis United Kingdom 89 10.0k 0.5× 10.8k 0.8× 6.8k 0.9× 2.1k 0.4× 5.1k 1.3× 851 37.5k
Peter R. Young United States 74 4.1k 0.2× 11.3k 0.9× 453 0.1× 5.5k 0.9× 2.3k 0.6× 288 25.1k
Marc W. Kirschner United States 151 10.5k 0.5× 66.0k 5.1× 1.2k 0.1× 3.8k 0.6× 3.8k 1.0× 398 89.9k
Leroy Hood United States 140 6.8k 0.4× 43.1k 3.4× 2.9k 0.4× 19.9k 3.3× 5.8k 1.5× 730 75.8k
Richard Simon United States 92 8.7k 0.5× 8.4k 0.7× 6.6k 0.8× 2.3k 0.4× 5.2k 1.4× 352 35.9k
James R. Wright Canada 98 8.1k 0.4× 13.4k 1.0× 11.2k 1.4× 3.3k 0.5× 3.9k 1.0× 1.0k 39.1k
Jun S. Liu United States 83 4.0k 0.2× 24.1k 1.9× 3.7k 0.5× 3.7k 0.6× 3.9k 1.0× 483 44.0k
Robert A. Gatenby United States 75 5.2k 0.3× 11.1k 0.9× 3.6k 0.5× 1.3k 0.2× 10.2k 2.7× 337 26.9k
Akira Suzuki Japan 76 3.0k 0.2× 13.8k 1.1× 1.9k 0.2× 2.7k 0.5× 2.9k 0.8× 998 32.6k
Michael Simons United States 97 3.2k 0.2× 18.7k 1.5× 2.3k 0.3× 2.7k 0.4× 4.1k 1.1× 432 34.6k

Countries citing papers authored by James Larkin

Since Specialization
Citations

This map shows the geographic impact of James Larkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Larkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Larkin more than expected).

Fields of papers citing papers by James Larkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Larkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Larkin. The network helps show where James Larkin may publish in the future.

Co-authorship network of co-authors of James Larkin

This figure shows the co-authorship network connecting the top 25 collaborators of James Larkin. A scholar is included among the top collaborators of James Larkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Larkin. James Larkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Larkin, James, et al.. (2025). Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges. Expert Opinion on Biological Therapy. 25(3). 245–256. 1 indexed citations
3.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591. 7 indexed citations
4.
Wiggins, Jennifer, Hao Tang, Keyur Desai, et al.. (2023). Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.. Journal of Clinical Oncology. 41(16_suppl). 9577–9577. 3 indexed citations
5.
Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.
6.
McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1020–1028. 90 indexed citations
7.
8.
Piperno‐Neumann, Sophie, James Larkin, Richard D. Carvajal, et al.. (2020). Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Molecular Cancer Therapeutics. 19(4). 1031–1039. 41 indexed citations
9.
Khushalani, Nikhil I., Adi Diab, Paolo A. Ascierto, et al.. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology. 16(28). 2165–2175. 17 indexed citations
10.
Mason, Robert M., Lewis Au, Alvaro Ingles Garces, & James Larkin. (2019). Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opinion on Pharmacotherapy. 20(9). 1135–1152. 34 indexed citations
11.
Masiero, Massimo, Demin Li, Pat Whiteman, et al.. (2019). Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy. Molecular Cancer Therapeutics. 18(11). 2030–2042. 31 indexed citations
12.
Wongchenko, Matthew, Grant A. McArthur, Brigitte Dréno, et al.. (2017). Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research. 23(17). 5238–5245. 28 indexed citations
13.
Yousaf, Nadia, et al.. (2015). The cost of ipilimumab toxicity. Melanoma Research. 25(3). 259–264. 17 indexed citations
14.
Seifert, Heike, Eishu Hirata, Martin Gore, et al.. (2015). Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell & Melanoma Research. 29(1). 92–100. 31 indexed citations
15.
Bridgeman, Victoria L., Elaine Y. Wan, Shane Foo, et al.. (2015). Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics. 15(1). 172–183. 38 indexed citations
16.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
17.
Karapanagiotou, Eleni, Victoria Roulstone, Katie Twigger, et al.. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. 18(7). 2080–2089. 151 indexed citations
18.
Girotti, María Romina, Malin Pedersen, Berta Sanchez‐Laorden, et al.. (2012). Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer Discovery. 3(2). 158–167. 272 indexed citations
19.
Kirkwood, John M., Lars Bastholt, Caroline Robert, et al.. (2011). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research. 18(2). 555–567. 218 indexed citations
20.
Chakrabarty, Deepto, P. Roche, M. H. van Kerkwijk, & James Larkin. (1997). Optical/IR Observations of the Low-Mass X-Ray Binaries GX 1+4 and 4U 1626-67. 190.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Ellis Breakdown of academic impact, for papers by Peter R. Young Breakdown of academic impact, for papers by Marc W. Kirschner Breakdown of academic impact, for papers by Leroy Hood Breakdown of academic impact, for papers by Richard Simon Breakdown of academic impact, for papers by James R. Wright Breakdown of academic impact, for papers by Jun S. Liu Breakdown of academic impact, for papers by Robert A. Gatenby Breakdown of academic impact, for papers by Akira Suzuki Breakdown of academic impact, for papers by Michael Simons
Rankless by CCL
2026